#USA #Tampa #Psilera #Psychedelic Therapies #PSIL-006

Psilera Praises Executive Order on Psychedelic Therapies

In a pivotal development for the mental health landscape, Psilera, a prominent biopharmaceutical company, has applauded a recent Executive Order aimed at prioritizing psychedelic therapies. Signed on April 18, 2026, the order titled "Accelerating Medical Treatments for Serious Mental Illness" represents a significant shift in federal policy, placing emphasis on the research, review, and accessibility of treatments derived from psychedelics.

Chris Witowski, PhD, Co-Founder and CEO of Psilera, stated, "This is a watershed moment for patients and researchers alike. The Executive Order signals a clear mandate for innovation and validates the transformative potential of psychedelic-based treatments we design and research. At Psilera, we are accelerating our own pipeline of novel neuroplastogens that build off the foundations of psychedelic molecules."

This Executive Order is particularly timely for Psilera, as the company gears up for the first-in-human trials of its flagship compound, PSIL-006, scheduled for 2027. Leveraging an extensive portfolio of intellectual property and cutting-edge drug design capabilities, Psilera is focused on optimizing the neuroplastic benefits of psychedelics while addressing cardiovascular risks, enhancing safety, and expanding access to a broader population.

As the landscape for psychedelic research continues to evolve, Psilera is actively participating in several key industry events:

• - April 28, 2026: 2nd Annual Neuroscience Innovation Partnering and Licensing Summit, where Dr. Jackie von Salm will speak on a panel.
• - June 10, 2026: Oppenheimer CNS Focus Event featuring a panel by Chris Witowski, PhD.
• - June 22-25, 2026: Bio International Convention attended by Chris Witowski, PhD, and Chief Medical Officer, Magali Haas, MD/PhD.
• - September 15, 2026: 9th Annual Neuropsychiatric Drug Development Summit with Magali Haas, MD/PhD, as a panel speaker.

Psilera is committed to advancing its ambitious pipeline of next-generation psychedelics and neuroplastogens. Their lead compound, PSIL-006, is part of a broader suite of therapeutic neuroplastogens specifically designed to assist those suffering from treatment-resistant depression (TRD).

With a mission centered on scientific excellence and an unwavering commitment to enhancing patient experiences, Psilera is at the forefront of pioneering innovative therapies through precision neuroscience. The firm aims to reshape the therapeutic landscape, demonstrating the profound impact that psychedelics can have on mental health treatment by encouraging normal neural function and emotional resilience.

For further information on Psilera's innovative therapeutic approaches, visit www.psilera.com. This landmark announcement adds momentum to Psilera's mission and opens new avenues in the exploration of psychedelic treatments, paving the way for potentially life-changing therapies that can alter the current state of mental health care.

As the conversation around psychedelics and mental health evolves, patient advocacy and scientific inquiry will play crucial roles in shaping effective and accessible therapies. The support articulated in the Executive Order underscores a broader societal willingness to explore these options, urging continued research and clinical validation in the years ahead.